Regenxbio Inc
(NAS:RGNX)
$
9.92
-0.09 (-0.9%)
Market Cap: 491.49 Mil
Enterprise Value: 320.09 Mil
PE Ratio: 0
PB Ratio: 1.63
GF Score: 65/100 Regenxbio Inc at Stifel Healthcare Conference Transcript
Nov 14, 2023 / 08:00PM GMT
Release Date Price:
$19.05
(+7.38%)
Annabel Eva Samimy
Stifel, Nicolaus & Company, Incorporated, Research Division - MD
All right. Good afternoon, everyone, we're going to get started here. We've got REGENXBIO presenting with us today. And it's our pleasure to have Kenneth Mills CEO; and Steve Pakola...
Stephen Pakola
REGENXBIO Inc. - Executive VP & Chief Medical Officer
CMO.
Annabel Eva Samimy
Stifel, Nicolaus & Company, Incorporated, Research Division - MD
CMO, I knew that. And maybe I can just give you a couple of minutes, you can give us a quick overview and then we can just touch into questions.
Kenneth T. Mills
REGENXBIO Inc. - President, CEO & Director
Sounds great. Thanks for having us. And we are an AAV gene therapy company that has been focused on the development of treatments in retinal diseases as well as muscle disorder for -- been public since 2015, we have a significant partnership that we started in 2021 with AbbVie that has helped launch our RGX-314 and now ABBV-RGX-314
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot